Graft-versus-host disease - From the bench to the bedside?

New England Journal of Medicine

Volumn 353, Issue 13, 2005, Pages 1396-1397

  Socié, Gérard ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; THYMOCYTE ANTIBODY;

CLINICAL FEATURE; DRUG MEGADOSE; EDITORIAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPH NODE IRRADIATION; LYMPHATIC LEUKEMIA; MORTALITY; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ACUTE DISEASE; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHATIC IRRADIATION; MALE; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 25444473896     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058175     Document Type: Editorial

References (13)

1. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324:667-74.
2. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-8.
3. Socie G, Cahn JY. Acute graft-versus-host disease. In: Barrett AJ, Treleaven J, eds. The clinical practice of stem-cell transplantation. Oxford, England: Isis Medical Media, 1998:595-618.
4. Couriel D, Caldera H, Champlin RE, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004;101:1936-46.
5. Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program) 2001:375-91.
6. Little MT, Storb R. The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain. J Clin Invest 2000;105:1679-81.
7. Satwani P, Harrison L, Morris E, Del Toro G, Cairo MS. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 2005;11:403-22.
8. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004;10:178-85.
9. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62.
10. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003;9:1144-50.
11. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002;196:389-99.
12. Zeng D, Lewis D, Dejbakhsh-Jones S, et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999;189:1073-81.
13. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005;353:1321-31.